A Novel Approach To Improving Cancer Care
New in-vitro diagnostics are needed to monitor and predict cancer metastasis. This would help stratify patients for optimal treatment and follow-up care.
We are developing cancer diagnostics that will give clinicians the power to detect and predict metastasis with high specificity and sensitivity. With these tests we will redefine the cancer care pathway.
Winner of AHSN Accelerator 2020
We were awarded £210K in non-diluting seed funding and are looking for investors and partners to join us on this exciting journey to change lives and improve healthcare.
Contact us on info@MetaGuideX.com
The MetaGuideX Team
Dr Ryan Pink
CEO/Co-Founder
Co-inventor
Board member on multiple Oxford healthcare organisations
Biotech consultant for companies like ThermoFisher and Bioline
Clinical researcher €6m Siemens cancer diagnosis tech
Dr Mark Beggs
COO
Experience with Pfizer, Janssen, AstraZeneca and GSK
CEO, UK Biocentre: quadrupled revenue to >£4m pa
Chief Executive, Stratified Medicine Scotland
Prof Dave Carter
Co-Founder
Present UK EV society President
Raised >£1.3m in academic and commercial funds
Lead inventor on the patents underpinning MetaGuideX
Emanuela Carollo
R&D lead
Entrepreneurial lead on Innovate UK application
Led MetaGuideX’s int. market research
Contact us on info@metaguidex.com
MetaGuideX Ltd – Company number 12549905